Research Article
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Table 1
Patients and tumor basic characteristics.
| | Characteristic | Total patients () | Percentage |
| | Age (years) | | | | Median (range) | 61 (33-80) | | | ≥61 | 21 | 53.8% | | <61 | 18 | 46.2% | | Gender | | | | Male | 26 | 66.7% | | Female | 13 | 33.3% | | ECOG performance status score | | | | 0-1 | 25 | 64.1% | | 2 | 14 | 35.9% | | Primary lesion | | | | Gastric | 30 | 76.9% | | Gastroesophageal junction | 9 | 23.1% | | Lines of previous treatment | | | | 1 | 4 | 10.3% | | ≥2 | 35 | 89.7% | | Previous targeted drugs therapy | | | | Yes | 7 | 17.9% | | No | 32 | 82.1% | | History of gastrectomy | | | | Yes | 17 | 43.6% | | No | 22 | 56.4% | | Number of metastatic sites | | | | ≤2 | 9 | 23.1% | | >2 | 30 | 76.9% | | HER2 expression status | | | | Positive | 1 | 2.6% | | Negative | 17 | 43.6% | | Not available | 21 | 53.8% | | Initial dosage of apatinib (mg) | | | | 500 | 22 | 56.4% | | 250 | 17 | 43.6% | | PD-1 blockades | | | | Camrelizumab | 26 | 66.7% | | Sintilimab | 8 | 20.5% | | Nivolumab | 5 | 12.8% |
|
|
Abbreviations: ECOG: Eastern Cooperative Oncology Group; HER2: human epidermal growth factor receptor 2; PD-1: programmed cell death protein 1.
|